Outlines how focusing on subpopulations with biomarkers could make the pre-clinical and clinical phases of drug innovation more efficient and create economic returns. Looks at collaborations with nonprofits to reduce risk and secure early-stage funding.
This web page is marked up with Schema.org microdata. Much of the necessary microdata is embedded within the HTML that creates the display you see above. The data that shows below is formatted for machine-reading and rounds out the complete descriptive set for this resource. Want more info about all of this? Go here. You can also view the complete dataset for this resource the way a machine sees it here .
Title: Assessing Risk and Return: Personalized Medicine Development & New Innovation Paradigm
Publication date 2008-10-01
Publication Year 2008
Frank L. Douglas
, Lesa Mitchell
Ewing Marion Kauffman Foundation
, clinical trials
, disease organizations
, personalized medicine
Resource provided by IssueLab